Electrospray fabrication of doxorubicin-chitosan-tripolyphosphate nanoparticles for delivery of doxorubicin
Archives of Pharmacal Research, ISSN: 0253-6269, Vol: 34, Issue: 4, Page: 583-592
2011
- 110Citations
- 161Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations110
- Citation Indexes110
- 110
- CrossRef45
- Captures161
- Readers161
- 161
Article Description
This work focused on a new technique for the preparation of doxorubicin (DOX) loaded chitosan (CS) nanoparticles (DOX-CS) - formation by electrospray ionization in the presence of tripolyphosphate (TPP) as the stabilizer. The working distance, needle gauge, flow rate, stirring rate, electrospraying voltage and DOX to CS molar ratio were sequentially and individually optimized and found to be a 26 gauge needle, an applied voltage of 13 kV, a flow rate of 0.5 mL/h, a working distance of 8 cm and a stirring rate of 400 rpm. The incorporation of chemically unchanged DOX with the CS into the particles was ascertained by Fourier transformed infrared spectroscopy (FT-IR), differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA). Under these optimized conditions, the DOX-CS particles were found to be nanoparticles of approximately 300 - 570 (dry particles) or 530 - 870 nm diameter (hydrated particles), with a PDI and SPAN polydispersity indices of 0.97 - 0.82 and 0.62 - 0.64, respectively, for initial DOX loading levels of 0.25 - 1%, as determined by SEM and particle size analyzer, respectively. Moreover, a high encapsulation efficiency (EE) of DOX into the nanoparticles was attained, ranging from 63.4 to 67.9% EE at 1 to 0.25% DOX loading. Finally, the in vitro DOX release behaviors of the DOX-CS particles revealed a prolonged release of DOX over at least seven hours.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=79960414044&origin=inward; http://dx.doi.org/10.1007/s12272-011-0408-5; http://www.ncbi.nlm.nih.gov/pubmed/21544723; http://link.springer.com/10.1007/s12272-011-0408-5; http://www.springerlink.com/index/10.1007/s12272-011-0408-5; http://www.springerlink.com/index/pdf/10.1007/s12272-011-0408-5; https://dx.doi.org/10.1007/s12272-011-0408-5; https://link.springer.com/article/10.1007/s12272-011-0408-5
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know